Results of the CLL2-GIVe trial in patients with previously untreated CLL harboring TP53 alterations. The combined targeting of CD20 (obinutuzumab), BTK (ibrutinib), and BCL-2 (venetoclax) leads to an impressive reduction in CLL tumor load, demonstrated by undetectable MRD in PB and BM in a high proportion of treated patients. Professional illustration by Patrick Lane, ScEYEnce Studios.